We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Summary
The Product Information (PI) documents for all selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) have been aligned to reflect the risk of sexual dysfunction persisting in some patients after drug cessation.
Sexual dysfunction is a known risk of SSRIs and SNRIs and these medicines already carry this warning. However, the caveat that this effect can persist even after patients stop treatment was not present in some of the PIs in this drug class.
Sexual dysfunction can refer to disorders of sexual drive (reduced or loss of libido), arousal and orgasm, and ejaculation. Patients may also report associated painful intercourse (dyspareunia), prolonged erection (priapism) or genital numbness. These effects can persist for weeks to years and can significantly harm patients’ quality of life.
Persistent sexual dysfunction after treatment is stopped is thought to be rare[1]. However, these symptoms are likely to be underreported and their prevalence is not currently known.
What health professionals should do
Health professionals should be alert to this issue and consider if current or previous antidepressant use could be a factor in patients reporting sexual dysfunction.
This adverse event is likely to be underreported and we encourage health professionals to report if they are suspicious of an association.
Background
SSRIs and SNRIs are widely used antidepressants in Australia. They are approved for major depression and anxiety disorders (obsessive compulsive disorder (OCD), social anxiety disorder, panic disorder and generalised anxiety disorder).
In addition to the original brands, there are numerous generic versions of these medicines.
Medicines in this class include:
- SSRIs – citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine and sertraline.
- SNRIs – desvenlafaxine, duloxetine and venlafaxine.
Cases of persistent sexual dysfunction
We have received 89 reports describing sexual dysfunction with an SSRI or SNRI in our Adverse Event Management System database (to April 2024). Of these, 4 described persistent sexual dysfunction after treatment was stopped. The 3 men and one woman ranged in age from 18 to 42. Reported symptoms included difficulty reaching orgasm, weakened orgasms, erectile dysfunction and reduced penile sensation. The effects persisted for 12 months to 3.5 years.
Cases of persistent sexual dysfunction have also been reported globally. One study of SSRIs, SNRIs, finasteride and isotretinoin identified 300 case reports[2]. The majority were associated with SSRIs and SNRIs (218 of 300 cases) with escitalopram, citalopram, paroxetine, sertraline, and fluoxetine accounting for 62% (186 out of 300 cases). Patient ages ranged from 15 years to 66 years with most patients being male (170 males vs 49 females). Duration of treatment ranged from a single dose to more than 16 years. In many cases, sexual dysfunction only presented or became worse when treatment was stopped.
PI updates
The PIs of all SSRIs and SNRIs already warn of the risk of sexual dysfunction during use of these medicines.
Three products – desvenlafaxine, sertraline and venlafaxine – already carry warnings about persistent sexual dysfunction.
Updated warnings were needed for 6 products: citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, and paroxetine, as follows:
4.4 Special warnings and precautions for use:
Sexual dysfunction
Selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs) may cause symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRI.
The latest Product Information (for health professionals) and Consumer Medicine Information (for patients) for these antidepressants are available on TGA eBusiness services.
References
| [1] | Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust. 2020 Apr;212(7):329-334. 16:796. doi.org/10.3390/jcm10040796 |
|---|---|
| [2] | Healy D, Le Noury J, Mangin D. 2018. Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors: 300 cases. International Journal of Risk & Safety in Medicine 29(3-4): 125-134. |
What to report? You don't need to be certain, just suspicious!
We encourage the reporting of all suspected adverse reactions to medicines, including vaccines, over-the-counter medicines, herbal, traditional or alternative remedies.
We particularly request reports of:
- all suspected reactions to new medicines (look for the Black Triangle ▼ in PI and CMI documents – this symbol identifies medicines that are new or being used differently)
- all suspected medicines interactions
- suspected reactions causing death, admission to hospital or prolongation of hospitalisation, increased investigations or treatment, or birth defects.
To report a suspected side effect or for more information about reporting, go to our ‘Report problem or side effect’ webpage.
Disclaimer
Medicines Safety Update is aimed at health professionals. It is intended to provide practical information to health professionals on medicine safety, including emerging safety issues. The information in Medicines Safety Update is necessarily general and is not intended to be a substitute for a health professional's judgment in each case, taking into account the individual circumstances of their patients. Reasonable care has been taken to ensure that the information is accurate and complete at the time of publication. The Australian Government gives no warranty that the information in this document is accurate or complete, and shall not be liable for any loss whatsoever due to negligence or otherwise arising from the use of or reliance on this document.
© Commonwealth of Australia 2024
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to tga.copyright@tga.gov.au.
For the latest safety information from us, subscribe to the TGA Safety Information email list via our website.
For correspondence or further information about Medicines Safety Update, contact our Pharmacovigilance Branch at ADR.Reports@health.gov.au.
Medicines Safety Update is written by staff from our Pharmacovigilance Branch.
Editor: Dr Megan Hickie
Deputy Editor: Aaron Hall
Contributors: Renae Mura & Dr Steph Cheung